Home Biosimilar Antibodies Immunology & Inflammation Interleukins inhibitor Secukinumab (anti-IL-17A) For research use only.
Not for use in humans.

Secukinumab (anti-IL-17A)

Synonyms: AIN457

Secukinumab (anti-IL-17A) (AIN457) is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is applied for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. MW=147.9 kDa.

Secukinumab (anti-IL-17A)

Click to purchase the isotype control of Secukinumab (anti-IL-17A)

Selleck's Secukinumab (anti-IL-17A) has been cited by 2 publications

Purity & Quality Control

Batch: A202501 Purity: 99.82% Protein concentration: 5.00mg/ml Endotoxin Level: <1EU/mg
99.82

Choose Selective Interleukins Inhibitors

Name Citation IL-6 IL-1 IL-8 IL-12 IL-10 IL-13 IL-2 Others
SKF-86002 0
JTE-607 Dihydrochloride 0 TNF-alpha
A-740003 2 rat P2X7 receptor,human P2X7 receptor
Apilimod mesylate 3 PIKfyve
MD2-TLR4-IN-1 0 TLR4,TNF-α
Danirixin (GSK1325756) 2 CXCR2
Resatorvid (TAK-242) 50 TLR4,NO,TNF-α
Apilimod 14 PIKfyve
LMT-28
Atractylodin NAAA
Triolein ROS,MMP-1
Ac-YVAD-cmk
Diethyl phosphate
RCM-1 STAT6,FOXM1,β-catenin
Stylopine COX-2,TNF-α,NO
Myrislignan NF-κB,COX-2,iNOS
NE 52-QQ57 iNOS,TNF-α,PGE2
PKR-IN-C16 PKR
Falcarindiol STAT,ERK,JNK
Gardenoside P2X7 Receptor,P2X3 receptor,NF-κB
T-5224 c-Jun,c-Fos/AP-1,Adamts-5
IQ 3 TNF-α,JNK3,JNK1
Isuzinaxib (APX-115 free base) TNFα,MCP-1/CCL2,NOX2
AUDA p38,Smad3,TGF-β
SAR-20347 IFN-α,TYK2,JAK1
SU 5201
Madecassic acid TNF-α,COX-2,iNOS
Homoplantaginin NF-κB,IKKβ,TNF-α
2',5'-Dihydroxyacetophenone NF-κB,ERK1/2,iNOS
Forsythoside B NF-κB,TNF-alpha,IκB
Mulberroside A NF-κB,Caspase-1,NALP3
Chelidonic acid glutamate decarboxylase,Caspase-1,NF-κB
4-Methylesculetin MPO
Muscone TNF-α,NLRP3 inflammasome,NF-κB
Ossirene (AS101)
Methylthiouracil ERK1/2,NF-κB,TNF-α
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description Secukinumab (anti-IL-17A) (AIN457) is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is applied for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. MW=147.9 kDa.
In Vitro
In vitro

Secukinumab can reduce cell growth in the miR130b-knockdown OCI-ly10 co-culture system.[1]
Cell Research:

MTT assay was adopted to measure cell growth in the control inhibitor or miR130b inhibitor transfected OCI-ly10 co-culture system upon treatment with or without IL17 inhibitor.
In Vivo
In vivo

Secukinumab administration significantly attenuates AAV8-IRF8 mediated recruitment of neutrophils, also downregulates the autophagy level and inhibits the release of either autophagy-dependent or independent chemokines in vivo.[2]
Animal Research

Animal Models: C57BL/6 mice, IRF8 FLOX mice (C57BL/6J background)
Dosages: 200 μg
Administration: i.p.
Reference: https://pubmed.ncbi.nlm.nih.gov/34400126/
 

Product Details

CAS No. 1229022-83-6
Isotype Human IgG1
Source Human
Formulation PBS buffer, pH 7.2
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Secukinumab (anti-IL-17A) | Secukinumab (anti-IL-17A) supplier | purchase Secukinumab (anti-IL-17A) | Secukinumab (anti-IL-17A) cost | Secukinumab (anti-IL-17A) manufacturer | order Secukinumab (anti-IL-17A) | Secukinumab (anti-IL-17A) distributor